Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 41875
- Registration Number
- NCT05264168
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
- Target Recruit Count
- 234
- Registration Number
- NCT05262322
- Locations
- 🇬🇧
Royal Victoria Infirmary - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
🇬🇧Queen Elizabeth University Hospital - NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧Gloucestershire Royal Hospital - Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 529536
- Registration Number
- NCT05256797
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Dennis M. McNamara, MD, MS
- Target Recruit Count
- 250
- Registration Number
- NCT05180773
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- VarmX B.V.
- Target Recruit Count
- 105
- Registration Number
- NCT05152420
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 30
- Registration Number
- NCT05116995
- Locations
- 🇨🇦
Nova Scotia Health, Halifax, Nova Scotia, Canada
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Scotmann Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05088928
- Locations
- 🇵🇰
Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 89215
- Registration Number
- NCT05083455
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05038228
- Locations
- 🇬🇧
Pfizer Investigator, London, United Kingdom
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT05035277
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Oslo Univesity Hospital - Ullevål, Oslo, Norway
🇳🇴Oslo University Hospital - Rikshospitalet, Oslo, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.